Table 2.

Clinical trials with CD19CAR T cell

StudyNMedian age (range), yPrior allo-HCT (%)Prelympho disease (<5%) in the absence of EMD (%)Prior blinatumomab (%)CNSEMD (%)CR/CRi% (MRD %)Post-CAR allo-HCT in responders, %Relapse, %SurvivalCD19 relapse, %No. of pts who underwent leuk but no CAR TRef.
U Penn/ CHOP 30 14 (5-60) 18 (60) 6 (20) 3 (10) CNS-2 = 2 NR 90 (88) 3 (11) 7 (26) 6-mo EFS = 67% 3 (43) NR 22  
6-mo OS = 78% 
MSKCC 53 44 (23-74) 19 (36) 21 (48) 13 (25) None 5 (9) 83 (67) 17 (39) 25 (57) Median EFS = 6.1 mo 4 (16) 24 14  
Median OS = 12.9 mo 
Novartis multicenter 75 11 (3-23) 46 (61) NR NR CNS-2 = 1 NR 81 (81) 8 (13) 22 (36) 12-mo EFS = 50% 15 (68) 17 17  
CNS-3 = 1 12-mo OS = 76% 
NCI 21 13 (1-30) 8 (38) 5 (24) 0 (0) CNS-2 = 2 NR 67 (86) 10 (71) 2 (14) 5-mo LFS = 79% 2 (100) NR 42  
10-mo OS = 52% 
Seattle Children’s Hospital 45 12 (1-25) 28 (62) 15 (33) 6 (13) CNS-2 = 7 NR 93 (100) 11 (28) 18 (45) 12-mo EFS = 51% 7 (39) NR 21  
CNS-3 = 2 12-mo OS = 70% 
FHCRC 53 39 (20-76) 23 (43) 14 (26) 10 (19) CNS-2 = 5 18 (34) 85 (85) 18 (40) 22 (49) For responders, median EFS = 7.6 mo, and 6 (27) 41  
median OS= 20 mo = 
Hebei Yanda Lu Daopei Hospital, China 51 11 (3-68) and 24 (2-44)* NR 9 (18) NR 16 (31) 90 (88) 27 (60) 11 (24) Relapse = 60% vs 6% for responders who did and did not receive HCT (P = .023) 6 (55) NR 27  
COH 13 33 (24-72) 6 (46) 5 (38) 9 (69) None NR 100 (91) 8 (73) NR NR NR 37  
CARPALL 14 9 (1-19) 10 (71) 10 (79) 1 (7) CNS 2/3 = 2  86 (86) 0 (0) 6 (50) 12-mo OS = 63% 5 (83) 36  
12-mo EFS = 46% 
StudyNMedian age (range), yPrior allo-HCT (%)Prelympho disease (<5%) in the absence of EMD (%)Prior blinatumomab (%)CNSEMD (%)CR/CRi% (MRD %)Post-CAR allo-HCT in responders, %Relapse, %SurvivalCD19 relapse, %No. of pts who underwent leuk but no CAR TRef.
U Penn/ CHOP 30 14 (5-60) 18 (60) 6 (20) 3 (10) CNS-2 = 2 NR 90 (88) 3 (11) 7 (26) 6-mo EFS = 67% 3 (43) NR 22  
6-mo OS = 78% 
MSKCC 53 44 (23-74) 19 (36) 21 (48) 13 (25) None 5 (9) 83 (67) 17 (39) 25 (57) Median EFS = 6.1 mo 4 (16) 24 14  
Median OS = 12.9 mo 
Novartis multicenter 75 11 (3-23) 46 (61) NR NR CNS-2 = 1 NR 81 (81) 8 (13) 22 (36) 12-mo EFS = 50% 15 (68) 17 17  
CNS-3 = 1 12-mo OS = 76% 
NCI 21 13 (1-30) 8 (38) 5 (24) 0 (0) CNS-2 = 2 NR 67 (86) 10 (71) 2 (14) 5-mo LFS = 79% 2 (100) NR 42  
10-mo OS = 52% 
Seattle Children’s Hospital 45 12 (1-25) 28 (62) 15 (33) 6 (13) CNS-2 = 7 NR 93 (100) 11 (28) 18 (45) 12-mo EFS = 51% 7 (39) NR 21  
CNS-3 = 2 12-mo OS = 70% 
FHCRC 53 39 (20-76) 23 (43) 14 (26) 10 (19) CNS-2 = 5 18 (34) 85 (85) 18 (40) 22 (49) For responders, median EFS = 7.6 mo, and 6 (27) 41  
median OS= 20 mo = 
Hebei Yanda Lu Daopei Hospital, China 51 11 (3-68) and 24 (2-44)* NR 9 (18) NR 16 (31) 90 (88) 27 (60) 11 (24) Relapse = 60% vs 6% for responders who did and did not receive HCT (P = .023) 6 (55) NR 27  
COH 13 33 (24-72) 6 (46) 5 (38) 9 (69) None NR 100 (91) 8 (73) NR NR NR 37  
CARPALL 14 9 (1-19) 10 (71) 10 (79) 1 (7) CNS 2/3 = 2  86 (86) 0 (0) 6 (50) 12-mo OS = 63% 5 (83) 36  
12-mo EFS = 46% 

CHOP, Children Hospital of Philadelphia; CNS-2, central nervous system-2 defined as <5 white blood cells (WBC)/μl of cerebrospinal fluid (CSF) with presence of lymphoblasts; CNS-3, ≥5 WBC/μl CSF with presence of lymphoblasts; LFS, leukemia-free survival; leuk, leukapharesis; NCI, National Cancer Institute; pts, patients; U Penn, University of Pennsylvania. See Table 1 for expansion of other abbreviations.

*

First median age and range for patients with r/r ALL; second median age and range for patients only treated for MRD+ disease.

Only 11 were evaluable for response as one received less than the intended dose and the other one had an EMD CD19 lesion.

or Create an Account

Close Modal
Close Modal